The Medicines Company - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2016', provides an overview of the The Medicines Company's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by The Medicines Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of The Medicines Company - The report provides overview of The Medicines Company including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses The Medicines Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features The Medicines Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for The Medicines Company - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding The Medicines Company's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 The Medicines Company Snapshot 6 The Medicines Company Overview 6 Key Information 6 Key Facts 6 The Medicines Company - Research and Development Overview 7 Key Therapeutic Areas 7 The Medicines Company - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 The Medicines Company - Pipeline Products Glance 15 The Medicines Company - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 The Medicines Company - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 The Medicines Company - Early Stage Pipeline Products 19 IND/CTA Filed Products/Combination Treatment Modalities 19 Preclinical Products/Combination Treatment Modalities 20 The Medicines Company - Drug Profiles 21 bivalirudin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 cangrelor tetrasodium 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 clevidipine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (meropenem+ vaborbactam [INN]) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ABP-700 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 MDCO-216 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 fentanyl 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 oritavancin diphosphate 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Carboetomidate 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Methoxycarbonyl Carboetomidate 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Methoxycarbonyl Etomidate 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit Carbapenemase for Bacterial Infections 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tigecycline 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 The Medicines Company - Pipeline Analysis 41 The Medicines Company - Pipeline Products by Target 41 The Medicines Company - Pipeline Products by Route of Administration 42 The Medicines Company - Pipeline Products by Molecule Type 43 The Medicines Company - Pipeline Products by Mechanism of Action 44 The Medicines Company - Recent Pipeline Updates 45 The Medicines Company - Dormant Projects 55 The Medicines Company - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
The Medicines Company, Key Information 6 The Medicines Company, Key Facts 6 The Medicines Company - Pipeline by Indication, 2016 8 The Medicines Company - Pipeline by Stage of Development, 2016 10 The Medicines Company - Monotherapy Products in Pipeline, 2016 11 The Medicines Company - Combination Treatment Modalities in Pipeline, 2016 12 The Medicines Company - Partnered Products in Pipeline, 2016 13 The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2016 14 The Medicines Company - Pre-Registration, 2016 15 The Medicines Company - Phase III, 2016 16 The Medicines Company - Phase II, 2016 17 The Medicines Company - Phase I, 2016 18 The Medicines Company - IND/CTA Filed, 2016 19 The Medicines Company - Preclinical, 2016 20 The Medicines Company - Pipeline by Target, 2016 41 The Medicines Company - Pipeline by Route of Administration, 2016 42 The Medicines Company - Pipeline by Molecule Type, 2016 43 The Medicines Company - Pipeline Products by Mechanism of Action, 2016 44 The Medicines Company - Recent Pipeline Updates, 2016 45 The Medicines Company - Dormant Developmental Projects,2016 55 The Medicines Company, Other Locations 56 The Medicines Company, Subsidiaries 57
List of Figures
The Medicines Company - Pipeline by Top 10 Indication, 2016 8 The Medicines Company - Pipeline by Stage of Development, 2016 10 The Medicines Company - Monotherapy Products in Pipeline, 2016 11 The Medicines Company - Combination Treatment Modalities in Pipeline, 2016 12 The Medicines Company - Partnered Products in Pipeline, 2016 13 The Medicines Company - Pipeline by Target, 2016 41 The Medicines Company - Pipeline by Route of Administration, 2016 42 The Medicines Company - Pipeline by Molecule Type, 2016 43 The Medicines Company - Pipeline Products by Top 10 Mechanism of Action, 2016 44
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.